Ladies and gentlemen, thank you for standing by. And welcome to the Medtronic Fourth Quarter Earnings Conference Call. At this time, all participants' lines are in a listen-only mode. After the speakers' presentation, there will be a question-and-answer session. [Operator Instructions] Please be advised that today's conference call is being recorded.

I would now like to hand the conference over to Ryan Weispfenning, Vice President and Head of Investor Relations. Sir, the floor is yours..

Thank you. Good morning and welcome to Medtronic's fiscal year 2020 fourth quarter conference call and webcast.

During the next hour, Geoff Martha, Medtronic Chief Executive Officer; Karen Parkhill, Medtronic Chief Financial Officer; and Omar Ishrak, Medtronic Executive Chairman, will provide comments on the results of our fourth quarter and fiscal year 2020, which ended on April 24, 2020. After our prepared remarks, we'll be happy to take your questions.

First, a few logistical comments. Earlier this morning, we issued a press release containing our financial statements and the revenue by division summary. We also issued an earnings presentation that provides additional details on our performance.

During today's earnings call, many of the statements made may be considered forward-looking statements and actual results may differ materially from those projected in any forward-looking statement given risks and uncertainties, including those related to the impact COVID-19 has had and is expected to continue to have on our business.

Additional information concerning factors that could cause actual results to differ is contained in our periodic reports and other filings that we make with the SEC and we do not undertake to update any forward-looking statement.

Finally, unless we say otherwise, revenue rates and ranges mentioned during this call are given on a constant currency basis, which compares to the fourth quarter after adjusting for foreign currency. References to organic revenue growth exclude the impact of our Titan Spine acquisition and currency.

Reconciliations of all non-GAAP financial measures can be found in the attachment to our earnings press release or on our website at investorrelations.medtronic.com. With that, I'm now pleased to turn the call over to Medtronic Chief Executive Officer, Geoff Martha.

Geoff?.

products that just received regulatory approvals over the past few months; products under regulatory review; and products that are in clinical trials or preparing to enter clinical trials.

Starting with the products that recently received their regulatory approvals, the pandemic has interrupted some of our recent launches, given the delay in procedures.

This includes the European launches of our Percept PC deep brain stimulator, InterStim Micro rechargeable sacral nerve stimulator, Cobalt and Crome high power CRM devices, and the DiamondTemp ablation catheter. It also slowed the U.S.

launches of our AV fistula indication in our IN.PACT Admiral drug-coated balloon, our DTM therapy in Pain Stim, and our Micra AV pacemaker. It's worth noting that prior to the pandemic, Micra grew over 60% in the U.S. in both February and March. The good news is that as procedures come back, we expect these launches to pick up steam.

Moreover, we just received approval for Micra AV and our Reveal LINQ 2 cardiac diagnostic monitor in Europe, as well as U.S. approval for our Cobalt and Crome high power CRM devices, which we announced earlier this month.

Our Cobalt and Crome offerings should be particularly valuable in the current COVID-19 environment, as they are the first and only Bluetooth-enabled high power devices in the U.S. that allow for distance programming and better remote monitoring.

Regarding the second category of products, those in regulatory review, the pandemic doesn't currently appear to be affecting the approval process. As a result, we're expecting a number of approvals this quarter, including U.S. approvals for our InterStim Micro sacral nerve stimulator, our Percept PC deep brain stimulator, and our Reveal LINQ 2.

We're also expecting European approval this quarter of the Minimed 780G. In the U.S., we anticipate approval this summer of a new product we're calling Minimed 770G, which is Bluetooth-enabled and allows for wireless, over-the-air software upgrades, before launching our 780G later in the fiscal year.

In addition, 770G will be the first hybrid closed loop system available to patients aged 2-6. Patients who purchase the 770G will get the free software upgrade to 780G with our Advanced Hybrid Closed Loop algorithm upon approval.

We expect to show the pivotal results of our Advanced Hybrid Closed Loop algorithm in adults at the virtual ADA Conference in June.

With the third category of our pipeline, those that are enrolling clinical trials or preparing to enter clinical trials, the pandemic has slowed things down, as clinical trial startups and enrollments have been placed on temporary pause. This includes our soft-tissue robot, products in our Diabetes CGM sensor pipeline, and our RDN ON MED trial.

Regarding our soft-tissue robot, our ability to finalize system and pre-clinical testing has been delayed, and given the uncertainty of the pandemic, it's too early to update you on timelines. However, we're exploring ways to expedite this work, with the intent of minimizing the delay.

In Diabetes, we continue to be optimistic on our ability to close the competitive gap in continuous glucose monitoring sensors. We intend to submit data to regulatory agencies on our Zeus transmitter at the end of the summer, and we have completed verification of our Synergy sensor that will enable our IDE submission within the next few weeks.

And in renal denervation, we will combine our RDN ON MED data with our recently presented OFF MED data to support U.S. approval. Look, we are excited about creating the new renal denervation market with its potential to treat millions of patients with hypertension.

With all of these recently approved and near-term pipeline products, customer enthusiasm remains high, and collectively, these represent growth acceleration as we emerge from the pandemic. With that, let me now ask Karen to take you through a discussion of our fourth quarter financials and outlook.

Karen?.

Thank you. As Geoff mentioned, our fourth quarter organic revenue declined 25%, and adjusted EPS was $0.58 cents, a decline of 62%. We did have significant deleveraging down the P&L in the quarter, as we continued to invest for the future despite the lower revenue growth.

Gross margin declined by approximately 700 basis points, driven in large part by increased expenses as a result of COVID-19, including manufacturing facility cleaning, increased protective equipment, bonuses for our factory employees, and higher freight and obsolescence charges.

In addition, we experienced a negative impact from mix, as products in higher demand carried lower margins. And we continued to experience a year-over-year impact from increased China tariffs.

In addition to a lower gross margin, our operating profit was affected by continued R&D investment in our pipeline and continued spending in SG&A, as we purposely protected the variable compensation of our sales reps.

Below the operating profit line, our adjusted interest expense declined 30%, driven by our successful debt issuance and tender transactions that we completed last spring and summer. And our adjusted nominal tax rate was 12.6% for the quarter and 14.3% for the year. Both were favorably impacted by lower earnings and the jurisdictional mix of profits.

Excluding any non-recurring tax benefits we received in fiscal year ‘20, our adjusted nominal tax rate would have been approximately 15%. Despite the decline in earnings, we did not lose our focus on driving free cash flow.

In fact, we generated $6 billion for the fiscal year, converting 97% of non-GAAP earnings, well above our long-term target of 80%. And our financial position remains strong.

Over the past several years, we have made important decisions to maintain a healthy and robust balance sheet, which enable us to not only withstand significant disruption, but more importantly, maintain our focus on the long-term.

We have ample liquidity, with $10.9 billion of cash and investments as of the end of the quarter, and an undrawn $3.5 billion credit facility. In addition, we have no public debt maturing until March of 2021.

As we stay focused on the long-term, we will continue to allocate our capital to drive our growth strategies, including investing in our pipeline to accelerate our long-term organic revenue growth.

In addition, we have not slowed our business development activities, as we continue to look to supplement our organic growth drivers with inorganic opportunities, including minority investments and tuck-in acquisitions.

We also continue to focus on generating proper returns for you, our shareholders, through both our organic long-term growth and our strong dividend. As an S&P dividend aristocrat, Medtronic has increased our dividend over the past 42 years, and this morning, we will make it 43 by increasing our annual dividend $0.16.

Looking ahead, the uncertainty of the COVID-19 pandemic makes it difficult to provide our traditional annual and quarterly guidance. Instead, we are happy to provide our thoughts on the recovery. As you know, there are many factors that will influence its speed and trajectory, and these will vary by geography and therapy.

COVID case volumes and potential resurgence will certainly play a role, as will updates to recommendations from government agencies on the resumption of elective procedures and provision of non-COVID related healthcare. Hospital capacity will be another key factor.

We recognize that new protocols designed to ensure patient and provider safety can slow the return to full capacity. And some healthcare systems are planning to increase capacity by extending workdays or doing procedures on weekends, though this isn't the case in all regions.

Moreover, some hospitals are at this point maintaining surge capacity, in case there is a second wave. We are assuming that any potential second wave will be adequately contained, but we are watching this closely and are prepared for a range of scenarios.

While it’s still early, we believe we have seen the worst of procedure declines and are seeing encouraging signs of earlier-than-anticipated recovery in several places around the world. In fact, the recovery has begun in China, although it is gradual.

While the ultimate pace there is still uncertain, we've seen a reduction in our weekly decline in revenue over the first few weeks of May, with high-teens decline from the prior year.

In other parts of Asia, such as Japan and India, we are still experiencing severe year-over-year procedure declines, and we continue to expect lockdowns to impact our first quarter, while other markets like Australia, New Zealand, and Korea should continue to see recovery. In the U.S.

and Western Europe, we've started to see sequential revenue improvement and hope to see that continue. In May, we've seen our weekly revenue across Western Europe declining around 20% from the prior year, and the U.S. has been declining around 30% over the same period.

With all of this in mind, we currently expect first quarter revenue growth to be modestly worse than the fourth quarter for both the total company and each of our groups. To be clear, we are seeing encouraging signs in many geographies.

But our largest regions are likely to experience a full quarter of impact compared with just 5 or 6 weeks in the fourth quarter. And at this point, we expect second quarter to be better than the first, as the recovery continues, and sequential improvement through the remainder of the fiscal year.

By the time we reach the fourth quarter, we would expect to be back to more normal revenue growth on a 2-year stacked basis. Focusing on the first quarter, while there is still a lot of uncertainty regarding the recovery, we would expect RTG revenue to be the most challenged, followed by CVG, with both expected to decline more than the total company.

MITG and Diabetes are both expected to decline in the first quarter as well, however, they should be better than the company average. And remember, we have an additional selling week in the first quarter, something that happens every 5 or 6 years with our fiscal calendar.

Because this extra week already occurred the last week of April, during the time the impact of the pandemic was at its highest, we picked up only a minimal amount of additional revenue. On the bottom-line, we continue to plan for significant deleveraging in the near term.

We expect our gross margin to remain under pressure owing to product mix, lower volumes, and the extra cost of safety protocols. Where we have more than enough inventory to meet current demand, manufacturing plants may operate at less than full capacity, which could lead to period expensing of some fixed overhead costs.

With this in mind, our first quarter gross margin could be down a few points sequentially. As stated, we are not taking a short-term view when it comes to investment.

We believe in the strength of the company and are positioning ourselves to come out of this crisis even stronger as we continue to invest in our employees, our pipeline, and our product launches. Given this, the first quarter SG&A and R&D spend should be a couple hundred million dollars higher than the fourth.

Though, similar to revenue, we would expect operating profit to improve as we progress through the fiscal year. Regarding currency, the U.S. dollar has strengthened substantially since the pandemic began, especially against emerging markets currencies.

As a result, our FX impact is looking to be about $0.10 more negative to fiscal ‘21 EPS than a few months back and just over $0.20 for the fiscal year. Before I turn the call back over to Geoff, I would like to express my sincere gratitude to our employees around the world for their ongoing commitment to our mission.

I couldn't be more proud of our teams and the way they have worked together to support our customers and ensure patients have access to our life-saving therapies. Back to you, Geoff..

Thanks, Karen. Now, looking back at what we've accomplished since the start of the pandemic, we are in many ways already a stronger company as a result of our actions. We've reaffirmed our mission in a profound way.

When patients and healthcare workers urgently needed solutions that we couldn't provide alone, we turned to Tenet 2 of our mission for a path forward. Tenet 2 tells us to focus our efforts on biomedical engineering where we display maximum strength, but it also says to gather people and facilities that augment these areas.

And we did just that, forming new partnerships that enhance our biomedical expertise with additional technology, supply chain reach, and manufacturing capacity from other companies. We've also gone back to our roots as a company by re-instilling the value of close partnerships with our customers.

We're focused on our customers' needs during this pandemic, moving beyond just selling the best medical therapies, to using our expertise to bring broader solutions to the table. Feedback from customers and governments on our support has been incredibly positive, and they are grateful for our efforts.

And we're bringing these new solutions to market at record speed. Development timelines have been measured in hours and days, not weeks and months, and the output has been very impressive. This pace and impact has created a strong energy and spirit within Medtronic.

Despite the day-to-day challenges of the pandemic, our people are really engaged and excited to assist customers in the recovery. So now, as the world begins to recover, we're focused on emerging from this pandemic even stronger.

We're executing strategies and supporting investments that others in our industry, who are in a different financial position, have been unable to make. We're harnessing new partnerships, cutting through the bureaucracy and operating at a high sense of urgency and speed.

We're also sharpening our competitive edge to drive an even higher level of performance. As we emerge, we expect these investments will even be more evident in our attraction and retention of top talent, and in the new products and solutions that we're offering physicians, patients, and healthcare systems.

Now, for competitive reasons, I'm not going to get into the details of all of the actions we're taking. However, when you combine these new possibilities with our pipeline, I couldn't be more excited about the future. We will come out of this even stronger, and in doing so, create sustainable value for our shareholders and for society.

Finally, as many of you know, this is my first earnings call as CEO, which also means that this is Omar's last earnings call. So I want him to say a few words.

Omar?.

Thank you, Geoff. And, this is my 36th Medtronic earnings call, so it was definitely time to turn the job over to someone else. And you're just doing great..

Thanks, Omar..

The past nine years has really gone by fast, and it's been a pleasure getting to know all of you in the investment community, whether that was visiting your offices around the world, hosting you in Minneapolis, or meeting you at the conferences.

I sincerely appreciate all of the interest you've had in this company and in this industry, and the support that you've given me and the Medtronic management team over the years. As I look ahead, I have full confidence in Geoff and this leadership team to take the company forward.

The team has been incredibly focused on the recovery and has a number of plans in the works. We're operating from a position of strength, given the strong financial position of the company and the full and robust pipeline.

While I didn't expect to be turning over the CEO role during a pandemic, it's reassuring to know that the decisions that we've made over the past several years have prepared us for this time. I'm confident that we have the right engaged team in place to ensure that Medtronic emerges even stronger.

As you've heard me say many times before, healthcare is a perpetual growth opportunity, as the three universal healthcare needs of improving clinical outcomes, expanding access, and optimizing cost and efficiency will not go away. The Medtronic mission and focus on these growth opportunities is enduring.

I'm glad to have played a role in leading this storied company, and I'm sure its best days are ahead. I wish Geoff, the team, and all of our employees all the very best going forward. Geoff, back to you..

Mike Coyle, Bob White, Brett Wall, and Sean Salmon, here to answer your questions. As usual, we want to get to as many questions as possible, so please help us by limiting yourself to one question, and if necessary, a related follow-up question. If you have additional questions, please contact Ryan and our Investor Relations team after the call.

Operator, first question please..

Your first question comes from the line of Robbie Marcus with JP Morgan. Please go ahead with your question..

Geoff, maybe we can start with what you were talking about at the end of the call, which is why you're so optimistic that Medtronic will emerge stronger. It's something we've heard a lot of CEOs mention over the past quarter earnings here. But Medtronic is actually doing stuff.

You're paying employees, both your sales reps through this, you’re paying bonuses. To me, it seems like you're actually building culture during a really difficult time here.

But maybe just give me your thoughts on why that's not just lip service, but something that will actually materialize Medtronic coming out of this pandemic?.

Let me walk, there's several components to the answer. First, I got to start off with our financial position going into the crisis, I mean having a strong balance sheet makes a huge difference and lets us lead into this whole crisis and play offense.

And the actions that we took during the crisis, right, specifically, you mentioned some of them, to support our employees and -- through benefits programs and protecting our reps’ incentive compensation, especially they’re highly leveraged representatives, sales reps in United States and providing all of those safety measures et cetera, et cetera, so that they have both -- protecting their health but also reducing anxiety during this time.

That makes a big difference. And these employees’ morale right now is really high. And we -- I'm sure we'll get questions on this later. But we do see this strong early signs of the recovery, and our employees are ready to go without distraction, and they've used -- that we've used this time wisely.

So I think they're ready to go and it's going to continue for us. Because after all, innovation and commercialization is still a people game. And our customers, okay, so the same with our customers.

And we spent a lot of time partly because we were able to reduce employees’ anxieties, they could stay focused on our mission, our patients and our customers. And we spent a lot of time I mentioned in the commentary with our customers, and it was a different dialogue.

It wasn't just selling our therapies and their features which are great, but it was really how can we help them through this pandemic? And how can we help them come out the other side. And the dialogue we're having with customers is what I'm wanting to have since I've been here, I hate it when they call us vendors, suppliers. I hate those words.

But now we're sitting down with them and they really are -- they're using the word partner and then they're backing it up and really engaging us in their recovery plans and relying on us in their recovery plans.

And so we've put a lot -- we've been developing several programs that I really want to get into some of the details of those, because I do think they're unique, and I think they’re competitive advantage.

But things around patient confidence, protecting healthcare workers, hospital productivity, these are things we're putting in place with our larger partners in particular, but we think we've scaled these to even smaller hospitals, and it's really building momentum. So that's another component of it and then it's our pipeline.

So our pipeline going into this was strong. We talked about it on the commentary, a lot of these products -- now as we emerge, a lot of these products are hitting. We got a lot of approvals coming out. We mentioned the Micra and cardiac rhythm, the Cobalt and Crome approval, LINQ 2 just got approved in Europe.

Percept PC and DBS which coming from -- and the InterStim Micro and Pelvic Health. Coming from RTG myself, I mean these have been a long time coming and we sacrificed a whole lot to get these things out and really excited. We also have Stimgenics in pain, the recent acquisition, some ENT products, DiamondTemp and AFS and EU.

So there’s wave of products hitting the market at a great time. And then specifically though, how these products are positioned during this pandemic, the whole remote programming, remote monitoring capabilities that before were important but now are like critical, right? And I'm listening hospitals talk about making this standard-of-care.

And in fact, if and I'd say when that happens, we are well -- we're in a best position in the marketplace for that. And then secondarily, are hyper focused on complications because they don't want patients coming back. And we're very well positioned there as well with things like Micra and TYRX and I can go on. So those are the big ones.

And I started with the financial condition and I'm going to end with that one again. I think it's worth mentioning twice the fact that we have a strong balance sheet. If you add all that up -- and we're feeling good about how we come out of this thing.

And so we can debate how big the pie -- when the pie gets back to the normal size, but if we don't have a bigger slice of that pie, I'm going to be disappointed..

Maybe as a quick follow-up. Medtronic right now probably has the best balance sheet that it’s had in five plus years. You've been talking increasingly over the past 12 months or so about increased M&A.

With asset prices down 20% across the board, is this the right time for Medtronic to be going out to do M&A? And what are you seeing in terms of opportunity set out there right now?.

The short answer is, yes. I think it is a good time to do M&A, as you mentioned, asset prices are down. It doesn't mean that we lower our standards. I just think again we can play offense. And I think our focus remains the same on tuck-ins.

That can -- tuck-in acquisitions that can -- but I'm a little more partial to the tuck-ins that are more meaningful and can actually affect our growth rate, our long-term growth rate. Like I said, we don't buy growth, we grow what we buy. And so that's what we're focused on.

And like I said, there are some are some opportunities that at least I felt personally were out of our reach, too expenses before this and now we're kind of more in line with what we think are reasonable returns for those investments. So, yes..

We’ll take the next question please, Carmen.

Your next question is from the line of David Lewis with Morgan Stanley. Please go ahead with your question..

Karen, just two for you real quickly here. The furious, I wonder if you could just help us with recovery here into the first quarter. I know you said growth will be modestly worse in the first.

Can you just to help us kind of how you're thinking about progression of recovery, maybe across the next couple of months, but more specifically, given the stocking dynamic in the fourth quarter and the extra selling week in the first quarter. It just could be kind of a material swing.

I just wonder if you could help us with some of those dynamics you're heading into the first? And then had a quick follow up on margins..

Sure, David. Thanks for the question. As Geoff said, we are seeing encouraging and positive signs of recovery right now, particularly in our largest regions of China, the U.S. and Western Europe.

That said, as I mentioned, we do expect a full quarter impact in Q1 as opposed to the five to six quarters that we had in -- five to six weeks that we had in Q4. So we are expecting at this stage at least Q1 to be modestly worse in terms of revenue growth than Q4.

But we do expect improvement in Q2, and sequential improvement going forward into Q3 and Q4. And by the time we hit Q4, we do expect to be back to more normal revenue growth for us and we'd measure that on a two year stacked basis given a tough year-over-year comparison.

In terms of stocking and the extra selling week, I did mention that the extra selling week happened for us the very first week of our quarter, which was the end of April. And obviously, because that was such a depressed time, we're seeing minimal revenue impact from that extra selling week.

As we think about stocking, we have said starting last quarter that we intend to focus on driving revenue more evenly throughout our quarter and reducing the amount of full transactions that we have. We'll continue to do that every quarter this year. But we had a good head start obviously in the fourth quarter. .

And then obviously, from a margin perspective, fourth quarter should maybe not be the trough margin period. So would you see sort of the trough margin period in the business? And more specifically, that revenue recovery is super helpful.

How should margin and earnings recover relative to that revenue? I mean if you can get back to that normalcy quarter that you specified, is that the normal quarter for margins? Or should margins or earnings kind of lag that revenue recovery?.

Thanks for that question, David. In terms of margins, I did mention that we could see sequentially worse gross margins in the first quarter.

And that really as we think about the increased expenses due to COVID-19 along with the fact that should we choose to not run some of our manufacturing operations at full capacity, that we will have a potential move to period expensing some of the overhead in those manufacturing plants as opposed to rolling it onto inventory on our balance sheet.

And so that may cause margins in the first quarter to be a little bit worse than the fourth quarter. But we would expect to see margin improvement as we move into Q2 and then continued sequential improvement as we move into Q3 and Q4. And by the time we get to Q4, we would expect to be back to more normal margins on a constant currency basis.

As I mentioned, FX has become more of a headwind for us this fiscal year, and really due to the strengthening of the dollar, particularly against emerging market currencies. And at this stage, we're looking at an FX impact of about $0.20 to the bottom-line, which can obviously impact margins too.

But we're really seeing good signs of recovery right now. And we're very excited about what the future can hold even beyond FY '21. .

Yes, I think this is obvious, but I can't help myself from stating this that, from a revenue perspective, in particular Q1 is markedly worse than Q4, because of the extra five to six weeks of impact, but we are seeing early signs of recovery.

It may be too early to extrapolate that all throughout the year, but we're seeing faster than we anticipated, especially in Europe and U.S. And for sure Q1 is the trough..

Thanks, David. Carmen, next question, please..

Your next question is from the line of Bob Hopkins with BOA. Please go ahead with your question..

Just two things I would love to comment on and I'll list them both upfront in the interest of time. So, one is, I apologize is a little short-term. I just want to dig a little deeper on your comments on the upcoming first fiscal quarter.

I'm sorry if I missed this, but did you give a sense for what you're seeing in the month of May? Just trying to get a sense for what kind of improvement you're assuming from May to get to that total Q1 comment that you made? And then I was also wondering if you just may be offer us a quick comment on the upcoming diabetes data we're going to see at ADA.

Because I know in the past, you have commented that you do expect a time in range of around 80%? And just wondering if that is still the case. .

Yes. Thanks, Bob. I'll just talk about the month of May quickly. We are seeing encouraging signs, and particularly as we look at our largest regions in China and the U.S. and Western Europe. In China, where we had stronger declines in February and March of around 46%, we said we saw April declines of around 21%.

And now we're seeing declines in China in the high-teens. So, continued improvement there. And in Western Europe, where we saw declines in April of around 32%. In May, we're seeing declines of around 20%. So again, continued improvement in Western Europe.

And in the U.S., the picture is a bit crowded when we look at April because of our bulk purchases, but we're clearly seeing procedural improvement across the U.S. And in May, declines of around 30%, just in the first few weeks of May, which is better than what we had in April. .

And just to build on that in the U.S., I mean, Karen gave you the numbers. Anecdotally, we're getting texts, calls from hospital -- big health system CEOs, purchasing people, basically, indicating faster than anticipated recovery in many parts of the United States. And basically saying, are you guys ready, buckle up.

So that's two things I like about that. One, the encouragement; two, that they're talking us about these things. And so it's -- the Northeast is going to be a little slower. I think the patient fear factor is a little higher there because the virus hit harder in New York and Massachusetts, but other parts of the U.S., very optimistic.

So anyway, that's why we're thinking Q1 for us as the trial and we're starting with the trough rather and we're seeing the -- we’re starting to see encouraging signs here. On the second question, Bob, I think I'm going to ask a Sean -- Sean Salmon to answer that one.

Sean?.

Yes, thanks for the question Bob. So we'll have two data sets coming up at the ADA, the virtual ADA. The first of which is going to be a randomized study out of New Zealand, which serves as the CE Mark data. And the second one is the adult portion of the Advanced Hybrid Closed Loop data, which will be featured there.

And just one thing to set your expectations for that, really evaluated a number of different things in that study. Most importantly, we looked at targeting the glucose settings for patients with two different levels. One is the usual level that we have with 670 today.

And the other one is a more aggressive lower target and we're evaluating the safety of that. So as you look at those results, you'll see that there's a really a lot to unpack there. But we're very confident in the product, and look forward to sharing the results next month..

Great. Thanks, Bob. Our next question, please, Carmen..

Your next question is from the line of Kristen Stewart with Barclays. Please go ahead with your question..

I guess my question is just as you guys are thinking just kind of longer term and bigger picture, just thinking about kind of your earlier comments, I guess a couple quarters ago just kind of on the M&A landscape and you guys clearly have a very good balance sheet and Karen has done a great job just improving the cash flow for the company.

How are you just thinking about deployment of capital? Now you guys have the opportunity, I guess, to be potentially a little bit more aggressive on the M&A front.

Do you think this is the opportunity now to go out and do that? Or are you guys going to be a little bit more logical and waiting to see how the landscape shakes out just given COVID and the backdrop?.

And yes, I am -- coming in this new role, I definitely have even more of appreciation for the cash flow and I'm a little forgiving of all the grief that Karen gave you about generating more cash flow in my prior role, I am thanking her now for that.

But when it comes to M&A, we're not going to be watchful and waiting to see how COVID plays out or the economy.

I mean that -- we believe that the healthcare and medtech, the areas that we're in like we said earlier are going to come back and Karen indicated earlier in the call that we believe by our Q4 that our revenue growth on a two year stacked basis will be back to normal levels in profitability. So I mean, we feel like this is a hit.

Obviously, it’s a very difficult financial impact for everybody. But we do feel bullish on the future here of the market and then us as well. So we won't hold back to those reasons.

And like I said earlier in the call we're looking for -- mainly focused on tuck-in deals that are going to create long-term improvements to our weighted average market growth rate and allow us to -- there position us strategically. So tuck-in deals are what we're looking for.

I tend to prefer it -- we'll do various sizes, like $1 billion, that range because it has a bigger impact on our growth rate. So that's what we're looking for. And for sure the virus’ impact on the markets and prices, asset prices has, is going to help -- is going to make certain assets more attractive.

I hope that helps, hopefully answers your question..

Yes.

And just in terms of thinking through I would say more from a opportunity in different businesses that you have, has COVID or just kind of thinking through the landscape change, the different areas that you would look opportunistically, whether it would change your view on whether the tuck-in one on the cardio side or whether a tuck-in more you’d be thinking about like telehealth or any of those areas, does it change kind of where you would think you'd lay kind of your tips from more of a product or service oriented or anything like that?.

I wouldn't say it changes by the business areas. I mean the -- you mentioned -- we are going to be making investments, more investments in remote capabilities of our product and of our business model, quite frankly.

So whether it'd be remote programming of devices, remote monitoring of devices, remote case support, digital medical education and things like that.

So investing, this is an area where I think Medtronic as a company, as an enterprise, this is an area we can add value to our different business units by making investments like these that can scale across a lot of them.

Whether that's -- I don't know that, that needs to be M&A, there are some opportunities there that we're looking at, that are more around that that whole idea of remote, but also just organic investments and partnerships with large and small technology companies.

Like I mentioned in the commentary, I mean I was really blown away by how some of these other companies can augment our technologies, like whether it be Intel or there's a lot of smaller companies as well, augmenting our capabilities to be more virtual, to be more remote. And so I think the partners -- some partnership opportunities there.

So in the virtual area, it's -- the remote areas, it's organic investment, partnerships, including partnerships with other companies, and potentially some other things as well. That's one area that I would argue has definitely increased in terms of our focus. But nothing I wouldn't -- I can't think of anything that between the different businesses..

Thanks, Kristen. Let’s go to the next question please, Carmen..

Your next question is from the line of Pito Chickering with Deutsche Bank. Please go ahead..

As we sit back and look at the impact from COVID, it looks like the healthcare systems globally were unprepared to deal with a large scale respiratory pandemic.

And now that appears that the worse is behind us, it might be certain to having discussions with countries about the infrastructure investment needed to deal with the next wave or next pandemic. So for example, widespread respiratory monitoring or ventilators. Thanks so much..

Thanks for the question, Pito. The answer to that is, yes. And right now -- and maybe I’ll ask Bob to comment as well. But right now, we have a big focus on emerging markets, specifically, regarding COVID and other respiratory, other viruses.

And we’re pulling our portfolio together, between our ventilation portfolio, our capnography, SpO2 and our monitoring capabilities to provide, I’ll call them, standing up a lot more hospital capacity for these -- for the patients in these areas, I see -- with all those devices and how they work together, and providing solutions to these countries and -- that they don’t have today and the scale.

And I really think it’s not just a one-time event. I do think this will introduce these technologies to the emerging markets and help that become more of a standard-of-care, because they are under-penetrated today, so I do think it will have a long -- a lasting and longer-term impact as well.

And also Bob do you want to make any comments to that?.

Yes. Geoff, just to build on what you said, and you said it really well. We think we’re really uniquely positioned with our combination of technologies and capnography, pulse oximetry, ventilation. An example of this is, we were a key player in standing up the Javits Center in New York City.

And we think the opportunity as emerging markets, stand up ICUs and care theaters, that Medtronic will be there with them to do that.

And as Geoff mentioned, we’re seeing tremendous interest from governments around the world as they look not only to stockpile and build their ventilation capability, but how they think about it because, while we’re seeing great recovery in the markets that Karen and Geoff mentioned, this pandemic is still going to hit emerging markets in a pretty big way unfortunately.

And we want to be there to support it. So that’s it, Geoff. I think we’re really well positioned to capitalize on that..

Thanks, Bob. And the last thing I’d say to that, Pito, is we also have a business that does remote patient monitoring. We do a lot of remote patient monitoring for chronic comorbid patients in the VA in the United States.

And that business has really gotten an uptick of interest, and we’re positioning it more strategically to support patients in the pandemic so -- in a number of ways..

Thanks, Pito. Next question, please..

Your next question is from the line of Joanne Wuensch with Citibank. Please go ahead..

I just want to spend a few minutes on the TAVR franchise. That was a bit of a problem child on the fiscal year third quarter. How has that evolved? What did you see early in the cycle? And how did -- how do you see Dr. Popma’s new role, congrats on that hire, too? Thank you..

Well, Joanne, thanks for the question. Obviously, the issues in Q3, we talked about extensively on the last call, where we were very disappointed with the U.S. performance of TAVR given that we had procedural growth rates in, call it, the 14%, 15% range when the market was growing to double that, a little bit in the 30s. That was strictly a U.S.

issue as you recall, we were actually growing with the market, a little ahead of the market outside of the United States.

We talked a lot about how well we were refocusing sales forces and repositioning them back into large high-volume accounts where they had been basically being deployed into the start-up of new accounts with the NCD and increasing the sharpness of the messaging around our benefits of the super annular design that we have relative to better gradients and better hemodynamics.

We were very encouraged, actually with where things were headed during the course of Q4 and the first half and those first seven weeks. We actually grew in the high teens. And in fact, as we were exiting that seven-week period, so the last three to four weeks there, we were actually well north of 20% in terms of procedural growth rate.

Now while that’s still below the market, very good traction that we were seeing. And then obviously, in the last five weeks, six weeks of the quarter, obviously, we saw the impact of the pandemic hit that market pretty dramatically.

Of course, the other benefit that we had was the ACC data releases, where we saw very significant positive data coming in the bicuspid area or immobility and lethal thrombosis data and some data that was a little more problematic for one of our competitors.

So collectively, yes, we really like where we’re positioned in terms of pushing our messaging for our product and design. Obviously, the recovery is taking place currently now.

And as Geoff mentioned, Karen mentioned, we are very encouraged by the trends that we are seeing in terms of now five weeks of continuous improvement in terms of overall procedural growth in that period. So we are encouraged with where things are headed. And we’re thrilled with the addition of Dr. Popma to our team.

He is obviously one of the leading physicians in the area of structural heart and has just been instrumental in the support of our program over the years and guiding our program. And we think he will really help us with the messaging of our product for low-risk patients for bicuspid patients and in our clinical design and development.

So we are very, very excited about where our TAVR program is headed..

Thanks Joanne. Next question please, Carmen..

Your next question is from the line of Larry Biegelsen with Wells Fargo. Pleased to ahead..

Just I’ll ask both of mine upfront here.

You talked about some of the improvement you’ve seen in May across geographies, but I’d be curious to hear what segments are coming back faster, any surprises? Is it more of the emergent versus the elective procedures? Is it more inpatient versus outpatient? And are those the trends you expect to continue over the coming quarters here? Just second, Bob, since it’s such an important product, any more color on the delay to the surgical robot? Just curious why pre-clinical testing would be delayed by COVID.

And is it -- are there some tweaks you’re making? Is that also a part of it? And should we just think about this, Bob, as maybe a couple of quarter delay? Is that the best way to think about it right now? Thanks for taking the questions, guys..

Well, Larry, maybe I’ll start on the first question, and I might ask Mike Coyle to comment a little bit, too, and then we’ll turn it over to Bob for the robot question. I’d say on the -- in terms of the recovery and the procedures, the recovery -- in summary, I say this kind of makes sense for us in terms of the rates of the recovery.

The therapies and products that are more urgent, if you will, or less deferrable are definitely coming back faster, like neurovascular and RTG, TAVR Mike mentioned, stents, cardiac rhythm, they’re coming back faster. And then the more deferrable procedures are taking longer, like our pelvic health franchise and RTG, for example.

But we’re seeing really strong data coming in on cardiac rhythm for a number of reasons. And maybe, Mike, you can talk to that for a second..

Yes. Obviously, the ones that we listed in our 8-K as being the least elective are the ones that are coming back the quickest. So in a cardiac surgery franchise, obviously, ECMO has seen a lot of significant growth, but pacemakers are coming back very quickly just given the symptomatic nature of the patients and their needing to be treated.

And it is playing extremely well for things like Micra, where we showed data of a 60% reduction in implant complications associated with pacemaker implants using Micra, that keeping patients out of the ICU right now is a big priority, and so that -- and TRYX, which is getting a significant increase in utilization in order to keep patients out of the hospital has been significant.

But as Geoff mentioned, I think the thing that probably has us the most encouraged is that moderately elective group of technologies, things like the ICDs, CRT, the TAVR and coronary stents. These are areas that we’re seeing a very nice rebound, especially over a very consistent rebound over the last five to six weeks.

And we’re even beginning to see in some of the less elective procedures like atrial fibrillation and our diagnostics business a very similar trend, although, obviously, trailing behind the others in terms of the rate of recovery. So as we said, it’s encouraging what we’re just seeing over the last five, six weeks..

Yes. Some of that is the market, and I think some of that, in the case of implantables or CVG implantables is how they’re positioned, with the remote capabilities, the distance programming, for example, and the lower complications, I think that’s helping as well, Larry. So maybe I’ll turn it over to Bob here for the robot question..

Yes. Thanks, Geoff. And Larry, thanks for the question. And certainly, as Geoff mentioned during his commentary, COVID has limited the pace at which we can really complete the required software system in pre-clinical testing. And Larry, this shows up in, I think, the impact in three ways.

First, our engineers have been forced to work remotely, and thus really limited access to the hardware and the robotic systems itself. Two, surgeons and OR staff have no ability yet to travel and participate in lab testing, and that’s had an impact; and then three, the availability of our external partners and sites to conduct some of the testing.

As you know, as I’ve talked to you about previously, we have software development and testing centers around the world, all of which have had impact on productivity. And then as I shared with you previously, we’ve certainly been working through the software development and integration challenges, that took us a bit longer and set us back as well.

But the thing I would leave you with, our team is looking at every single creative way to expedite our work related to the program, and we’re seeing some amazing creativity. But true, as Geoff mentioned, given the uncertainty of the pandemic, it’s too early to give you an update on time lines at this point. But thanks, Larry..

Thank you, Larry. We have time for one more question, Carmen. Take the last question, please.

Your final question will come from the line of Vijay Kumar with Evercore ISI. Please go ahead..

Hey, guys. Thanks for squeezing me and then, Omar, congratulations on your tenure here at Medtronic. Maybe just one quick one for me. Karen, I think you mentioned that, Q4 back to normalized growth, and you guys look at growth from a double-stack perspective? I just want to make -- clarify Q4 of ‘20, it was down 25.

Do you mean that Q4 of FY ‘21 will be up 25 plus. So on a double-stack basis, we’re back to growth? Just one clarification on that.

And then, Geoff, on the pipeline here, I think you mentioned InterStim Micro, Percept DBS, just maybe in a normalized environment, right, what kind of share gains or what kind of impact could we expect out from these products? Thank you..

Yes. So on your first question, Vijay, on what’s normal in Q4. Obviously, things are uncertain. And so we’re not giving specific guidance, because of that uncertainty. But just as we look forward right now, when we talk about a return to normal growth on a two-year stacked basis, we’re talking about normal around the mid single-digit levels.

And so you can expect that on a two-year stack basis. Hopefully that helps..

Yes. And Vijay, it’s Brett Wall with RTG. And related to these new neuromodulation products, particularly InterStim, pre-COVID in Europe where we had launched this technology, we took back 40% of the accounts that had been with the competitor. So we’re — that was pre-COVID. So we’re really thrilled with this new technology.

The technology itself is extraordinarily competitive. Every patient can get an MRI, whether it’s 1.5 or 3 Tesla. The product itself has a terrific battery recharging capabilities. The recharge experience is great for the patient. It has just significant ease of use for the patient.

And the device itself has a programmer that has the ability to have 11 different programs on the patient, which allows that patient and physician to make multiple changes versus the competitors, kind of, a plastic, single program device that doesn’t really allow any flexibility, particularly in a post-COVID world.

On the Percept device, this device, which we’ll also launch. Both these devices, we’ll launch this quarter in the United States. And that will put us back into a significant share taking mode. It’s the first device that’s going to have the ability to move forward and close the loop with DBS procedures and sense what’s happening in the brain.

And we’re going to be able to move forward and significantly alter the experience for the patient and also for DBS in general. So this is really a significant reboot across this entire franchise..

Thanks, Vijay.

Geoff, do you have any final remarks for us?.

Okay. Thanks, Ryan. So on behalf of our entire management team, I’d like to thank you for your continued support and interest in Medtronic. And hey, look, we look forward to updating you on our progress on our Q1’s earning call in August. And so please stay healthy and safe..

Thank you. Thank you, everyone, for joining today's conference call. You may now disconnect..